Balchem Co. (NASDAQ:BCPC) Shares Purchased by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE grew its position in Balchem Co. (NASDAQ:BCPC - Free Report) by 5.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,711 shares of the basic materials company's stock after buying an additional 2,393 shares during the quarter. Congress Wealth Management LLC DE owned 0.16% of Balchem worth $8,266,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Pathstone Holdings LLC raised its position in shares of Balchem by 6.5% during the 3rd quarter. Pathstone Holdings LLC now owns 10,361 shares of the basic materials company's stock worth $1,824,000 after purchasing an additional 632 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Balchem during the third quarter worth $1,153,000. Intech Investment Management LLC raised its holdings in shares of Balchem by 55.6% in the third quarter. Intech Investment Management LLC now owns 8,611 shares of the basic materials company's stock worth $1,516,000 after acquiring an additional 3,077 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Balchem by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 361,970 shares of the basic materials company's stock valued at $63,707,000 after acquiring an additional 7,562 shares in the last quarter. Finally, Citigroup Inc. boosted its stake in shares of Balchem by 61.1% during the third quarter. Citigroup Inc. now owns 43,178 shares of the basic materials company's stock valued at $7,599,000 after acquiring an additional 16,378 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Sidoti raised shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. Finally, HC Wainwright restated a "buy" rating and set a $190.00 target price on shares of Balchem in a research report on Monday, February 24th.

Balchem Trading Down 1.4 %

NASDAQ:BCPC traded down $2.32 during mid-day trading on Friday, reaching $163.79. The company's stock had a trading volume of 151,524 shares, compared to its average volume of 122,072. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03. The company's fifty day simple moving average is $165.26 and its two-hundred day simple moving average is $169.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. The stock has a market cap of $5.33 billion, a P/E ratio of 41.68, a P/E/G ratio of 4.41 and a beta of 0.63.

Balchem (NASDAQ:BCPC - Get Free Report) last released its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The company had revenue of $240.00 million during the quarter, compared to analysts' expectations of $239.96 million. On average, equities analysts predict that Balchem Co. will post 4.64 EPS for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.